Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Kathy Albain was named the inaugural Huizenga Family Endowed Chair in Oncology Research at Loyola University Chicago Stritch School of Medicine.

The endowed chair will enable Albain to devote more time to cancer research, and is recognition of the outstanding contributions she has made as a physician, researcher, teacher and mentor. The chair is funded by Heidi Huizenga, one of Albain’s grateful patients, her husband Peter, and her family.

Albain is a professor in the division of hematology/oncology in the department of medicine of Loyola University Chicago Stritch School of Medicine. She is director of Loyola Cardinal Bernardin Cancer Center’s breast clinical research program, co-director of the multidisciplinary breast oncology center and director of the thoracic oncology program.

Albain is a leader in national clinical trials of new treatments for breast and lung cancer as well as cancer survivorship research.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login